NEET-PG 2013 - Pharmacology Practice Questions

Q: Which of the following statements is true regarding omalizumab?

All of the options. ***All of the options*** is correct because each statement is true: **Anti-IgE** - Omalizumab is a **humanized monoclonal antibody** that specifically targets and binds to **free IgE** in the circulation - By binding free IgE, it prevents IgE from attaching to **high-affinity receptors** on mast cells and basophils - This reduces the allergic cascade and prevents release of inflammatory mediators **Given subcutaneously** - Omalizumab is administered via **subcutaneous injection** only - Dosing is typically every **2 to 4 weeks** based on patient's body weight and baseline IgE levels - Not available in oral or intravenous formulations for asthma treatment **Used as add-on therapy in moderate to severe asthma prophylaxis** - FDA approved as **add-on maintenance treatment** for patients aged ≥6 years with **moderate to severe persistent allergic asthma** - Indicated when asthma is **inadequately controlled** with inhaled corticosteroids - Reduces frequency of asthma exacerbations and improves asthma control - Also approved for chronic spontaneous urticaria All three statements accurately describe omalizumab's mechanism, administration route, and clinical indication, making **"All of the options"** the correct answer.

Q: Which route of administration undergoes the maximum first pass metabolism?

Oral. ***Oral*** - Drugs administered orally are absorbed from the **gastrointestinal tract** and transported via the **portal vein** directly to the liver, where they undergo significant **first-pass metabolism** before reaching systemic circulation. - This hepatic metabolism can drastically reduce the **bioavailability** of the drug, requiring higher doses or alternative administration routes. *Intra-arterial* - This route delivers drugs directly into an **artery** supplying a target tissue or organ, largely bypassing systemic circulation and initial hepatic metabolism. - It is used for localized effects, such as **chemotherapy** for specific tumors, minimizing systemic exposure. *Rectal* - While a portion of rectally administered drugs may bypass the portal circulation by entering the **inferior and middle rectal veins**, a significant amount can still be absorbed into the superior rectal vein, which drains into the portal system. - This means rectal administration offers only **partial avoidance** of first-pass metabolism, making it less complete than IV or intra-arterial routes for bypassing the liver altogether. *Intravenous* - Drugs administered intravenously are delivered directly into the **systemic circulation**, completely bypassing the gastrointestinal tract and the liver's first-pass metabolism. - This route ensures **100% bioavailability** and rapid onset of action, as the drug immediately reaches its target.

Q: Which of the following drugs is known to have low first pass metabolism?

Theophylline. ***Theophylline*** - **Theophylline** exhibits **low first-pass metabolism**, meaning a significant portion of the orally administered drug reaches systemic circulation unchanged. - This characteristic contributes to its relatively **high bioavailability** when given orally. *Lidocaine* - **Lidocaine** undergoes extensive **first-pass metabolism** in the liver, leading to very low oral bioavailability. - Due to this, it is typically administered **parenterally** (e.g., intravenously or topically) to achieve therapeutic concentrations. *Propranolol* - **Propranolol** is known for its significant **first-pass metabolism**, which results in a much lower bioavailability after oral administration compared to intravenous. - This extensive metabolism necessitates higher oral doses to achieve the same therapeutic effect as parenteral administration. *Morphine* - **Morphine** also undergoes substantial **first-pass metabolism** in the liver, where it is primarily glucuronidated. - This leads to a lower oral bioavailability compared to other routes of administration and contributes to a higher oral dose requirement.

Q: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?

Zero order kinetics. ***Zero order kinetics*** - This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time. - Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses. *First pass kinetics* - This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration. - While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses. *First order kinetics* - In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration. - Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated. *Second order kinetics* - This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants. - It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.

Q: Which of the following substances is not classified as a carcinogen for bladder cancer?

Isopropyl alcohol. ***Isopropyl alcohol*** - Research does not link **isopropyl alcohol** to an increased risk of bladder cancer, making it a non-carcinogenic substance in this context. - It is commonly used as a solvent and antiseptic, but has not shown **urogenic carcinogenicity** in studies. *Phenacetin* - **Phenacetin** is an analgesic that has been associated with an increased risk of bladder cancer, particularly due to its metabolite, which can be nephrotoxic. - Its use has significantly declined due to its carcinogenic effects on the urinary system. *Benzidine* - **Benzidine** is a well-known bladder carcinogen, primarily linked to the dye industry, where exposure has led to increased rates of bladder cancer [1]. - This substance has been implicated in **urothelial carcinoma** due to its mutagenic properties. *Acrolein* - **Acrolein** is a toxic compound that can cause bladder irritation and has been studied for its potential carcinogenic effects related to bladder cancer. - It is released during the combustion of materials and is known to contribute to **chemical injury** in the bladder. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 217-218.

Q: What is the best drug for control of acute esophageal variceal bleeding?

Octreotide. ***Octreotide*** - **Octreotide** is a somatostatin analog that causes **splanchnic vasoconstriction**, reducing portal venous inflow and pressure, which is crucial in controlling **esophageal variceal bleeding**. - Its mechanism involves inhibiting the release of **vasodilatory hormones** like glucagon, leading to a decrease in portal pressure without significant systemic side effects. *Vasopressin* - **Vasopressin** is a potent vasoconstrictor that can reduce portal pressure but has significant systemic side effects such as **myocardial ischemia** and **bowel ischemia** due to widespread vasoconstriction. - It is generally no longer considered the first-line pharmacological treatment for variceal bleeding due to its **adverse effect profile**. *GnRH* - **GnRH** (Gonadotropin-releasing hormone) plays a role in regulating the reproductive system by controlling the release of FSH and LH from the pituitary. - It has **no direct role** in the management or control of esophageal bleeding. *Propranolol* - **Propranolol** is a non-selective beta-blocker primarily used for **prophylaxis** of variceal bleeding by reducing portal pressure chronically. - It works by reducing cardiac output and causing splanchnic vasoconstriction, but it is **not used for acute control** of active bleeding.

Q: Which of the following reduces the efficacy of oral contraceptives?

Griseofulvin. ***Griseofulvin*** - **Griseofulvin** is an antifungal agent known to induce liver enzymes, specifically the **cytochrome P450 system**. - Enzyme induction accelerates the metabolism and clearance of **oral contraceptives**, leading to lower plasma concentrations and reduced efficacy. *Erythromycin* - **Erythromycin** is a macrolide antibiotic that typically inhibits liver enzymes rather than inducing them. - While it can interfere with the metabolism of some drugs, it usually **increases** rather than decreases the plasma levels of co-administered medications, and is not known to reduce oral contraceptive efficacy. *Disulfiram* - **Disulfiram** is used to treat chronic alcoholism and inhibits aldehyde dehydrogenase. - It does not significantly interact with the metabolism of **oral contraceptives** via the cytochrome P450 system or other mechanisms that would reduce their efficacy. *Cimetidine* - **Cimetidine** is an H2 receptor antagonist that is known to inhibit cytochrome P450 enzymes. - This inhibition would likely **increase** the plasma concentration of drugs metabolized by these enzymes, such as oral contraceptives, rather than reducing their efficacy.

Q: Which of the following is NOT a beta-2 agonist?

Ketotifen. ***Ketotifen*** - **Ketotifen** is an **oral anti-allergic drug** that acts as a **mast cell stabilizer** and **H1-antihistamine**, not a beta-2 agonist. - It is used for **prophylactic treatment** of asthma and allergic conditions, working through different mechanisms than bronchodilators. *Terbutaline* - **Terbutaline** is a **short-acting beta-2 agonist (SABA)** used for bronchodilation in asthma and COPD [2]. - Available in **oral, inhaled, and injectable forms** for rapid relief of bronchospasm. *Salbutamol* - **Salbutamol** (also known as albuterol) is a **short-acting beta-2 agonist (SABA)** and the most widely used rescue inhaler for asthma [1], [2]. - Provides **rapid bronchodilation** by stimulating beta-2 receptors in airway smooth muscles [3]. *Bambuterol* - **Bambuterol** is a **long-acting beta-2 agonist (LABA)** that is a prodrug of **terbutaline**. - It is slowly converted to the active form in the body, providing **sustained bronchodilation** for maintenance therapy.

Q: Beta2-agonists cause all except:

Hyperkalemia. ***Hyperkalemia*** - Beta2-agonists actually cause **hypokalemia**, not hyperkalemia, by promoting the intracellular shift of potassium. - This effect is due to the stimulation of the **Na+/K+-ATPase pump** by beta-2 adrenergic receptors. *Hyperglycemia* - Beta2-agonists can lead to **hyperglycemia** by promoting glycogenolysis and gluconeogenesis in the liver. - They also decrease **insulin secretion** and increase insulin resistance. *Tremor* - **Tremor** is a common side effect of beta2-agonists, particularly in the hands, due to direct stimulation of beta2 receptors on skeletal muscle. - This muscle stimulation leads to increased muscle twitching and a fine tremor. *Palpitation* - **Palpitations** can occur due to the systemic absorption of beta2-agonists, leading to activation of beta1 receptors in the heart. - This can cause **tachycardia** and a sensation of a racing heart.

Q: What is the mechanism of action of Abatacept?

Inhibitor of co-stimulation of T cells. ***Inhibitor of co-stimulation of T cells*** - Abatacept is a **fusion protein** that blocks the **CD28-CD80/86 co-stimulatory pathway**, which is crucial for full T-cell activation. - By binding to **CD80** and **CD86** on antigen-presenting cells, it prevents their interaction with **CD28** on T cells, thus inhibiting T-cell proliferation and cytokine production. *Tumor necrosis factor (TNF) alpha inhibitor* - TNF alpha inhibitors (e.g., **adalimumab**, **infliximab**, **etanercept**) bind to and neutralize **TNF alpha**, a pro-inflammatory cytokine. - While used in similar conditions, their mechanism is distinct from Abatacept's T-cell co-stimulation blockade. *Monoclonal antibody against interleukin-6 (IL-6) receptor* - Drugs like **tocilizumab** target the **IL-6 receptor**, blocking the signaling of **IL-6**, another important inflammatory cytokine. - This mechanism primarily affects cytokine signaling rather than directly inhibiting T-cell activation in the same way as abatacept. *Interleukin-1 (IL-1) receptor antagonist* - **Anakinra** is an example of an **IL-1 receptor antagonist**, which competes with IL-1 for binding to its receptor, thereby blocking its pro-inflammatory effects. - This mechanism focuses on inhibiting the action of IL-1, unlike Abatacept's role in T-cell activation.

Question 1

Which of the following statements is true regarding omalizumab?

Accepted Answer

All of the options

Answer

Anti-IgE

Answer

Given subcutaneously

Answer

Used as add-on therapy in moderate to severe asthma prophylaxis

Question 2

Which route of administration undergoes the maximum first pass metabolism?

Accepted Answer

Oral

Answer

Intra-arterial

Answer

Rectal

Answer

Intravenous

Question 3

Which of the following drugs is known to have low first pass metabolism?

Accepted Answer

Theophylline

Answer

Lidocaine

Answer

Propranolol

Answer

Morphine

Question 4

What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?

Accepted Answer

Zero order kinetics

Answer

First pass kinetics

Answer

First order kinetics

Answer

Second order kinetics

Question 5

Which of the following substances is not classified as a carcinogen for bladder cancer?

Accepted Answer

Isopropyl alcohol

Answer

Acrolein

Answer

Phenacetin

Answer

Benzidine

Question 6

What is the best drug for control of acute esophageal variceal bleeding?

Accepted Answer

Octreotide

Answer

Vasopressin

Answer

GnRH

Answer

Propranolol

Question 7

Which of the following reduces the efficacy of oral contraceptives?

Accepted Answer

Griseofulvin

Answer

Disulfiram

Answer

Erythromycin

Answer

Cimetidine

Question 8

Which of the following is NOT a beta-2 agonist?

Accepted Answer

Ketotifen

Answer

Terbutaline

Answer

Salbutamol

Answer

Bambuterol

Question 9

Beta2-agonists cause all except:

Accepted Answer

Hyperkalemia

Answer

Hyperglycemia

Answer

Tremor

Answer

Palpitation

Question 10

What is the mechanism of action of Abatacept?

Accepted Answer

Inhibitor of co-stimulation of T cells

Answer

Tumor necrosis factor (TNF) alpha inhibitor

Answer

Monoclonal antibody against interleukin-6 (IL-6) receptor

Answer

Interleukin-1 (IL-1) receptor antagonist

NEET-PG 2013 — Pharmacology